Get the Stockscreener App
4.37
0.23%
0.010
After Hours:
4.37
Verrica Pharmaceuticals Inc stock is traded at $4.37, with a volume of 72,849.
It is up +0.23% in the last 24 hours and down -11.54% over the past month.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
See More
Previous Close:
$4.36
Open:
$4.39
24h Volume:
72,849
Relative Volume:
1.15
Market Cap:
$75.07M
Revenue:
$37.16M
Net Income/Loss:
$-17.83M
P/E Ratio:
-4.2263
EPS:
-1.034
Net Cash Flow:
$-14.22M
1W Performance:
-1.80%
1M Performance:
-11.54%
6M Performance:
-5.41%
1Y Performance:
+6.85%
1-Day Range:
$4.36
$4.50
1-Week Range:
$4.355
$4.90
52-Week Range:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
4.37 | 75.07M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Verrica Pharmaceuticals stock trades at USD 4.10 - AD HOC NEWS
Verrica Pharmaceuticals stock holds steady as investors watch latest clinical and earnings signals - AD HOC NEWS
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals stock holds steady as investors look to lead product progress - AD HOC NEWS
VRCA: Phase III programs for common warts and BCC advance rapidly, with strong efficacy and global expansion - TradingView
Verrica Pharmaceuticals at H.C. Wainwright conference: growth and pipeline By Investing.com - Investing.com Canada
Verrica Puts Investor Focus on Dermatology Pipeline - MyChesCo
Net current asset value per share of Verrica Pharmaceuticals Inc. – HAM:1NE0 - TradingView
Number of shareholders of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - tradingview.com
Number of shareholders of Verrica Pharmaceuticals Inc. – HAM:1NE0 - TradingView
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences - marketscreener.com
Verrica Pharmaceuticals Inc. Balance Sheet – HAM:1NE0 - TradingView
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
A contagious skin infection affects about 6 million, mostly children. Verrica presents Sept. 14. - Stock Titan
Verrica Pharmaceuticals Stock Price Forecast. Should You Buy VRCA? - StockInvest.us
Verrica Pharmaceuticals Inc. (VRCA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills - MyChesCo
Verrica Pharmaceuticals (VRCA) Drops 4% to $5.46 as Support Level Comes into FocusIPO Entry Watch - siam.in
Breakout Bulletin: August 24-August 28 - dermatologytimes.com
Verrica completes enrolment in Phase III trial of Ycanth - Clinical Trials Arena
Technical Analysis on One NASDAQ- Listed Pharmaceuticals Stock: VRCA - kalkine.com.au
Verrica Completes Enrollment in Phase 3 YCANTH Common Warts Trial - Dermatology Times
VRCA Looks 46.0% Undervalued on GF Value™ Despite Speculative Ri - GuruFocus
Verrica (VRCA) Results Versus Estimates: The Bottom-Line Figure Trails Its Comparison in the Current Update; Share Move: Shares Move 1.04% Up at the CloseEarnings Miss Streak - dars.gov.et
Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current SessionGuidance Revision Trend - vinanet.vn
Verrica (VRCA) Update: Closes 0.82% Lower at $4.82 for the Current Session; Technical Setup: the Near-Term Reference Band Stretches From $4.58 to $5.06 on the DayHigh Volume Node - dars.gov.et
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Verrica (VRCA) Financial Results: EPS Misses Its Estimate in Latest Trading; Trading-Day Reaction: Shares Move 4.29% Lower on the DayReturn On Capital - vinanet.vn
Verrica Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares - MarketBeat
Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy - Stock Titan
Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August - Stock Titan
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals Inc (VRCA) (Q2 2026) Earnings Call Highl - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade PersistsAdvance Decline Volume - dars.gov.et
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
Needham Maintains Verrica Pharmaceuticals(VRCA.US) With Hold Rating - Moomoo
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison - TradingKey
Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):